With the first approval by the United States (U.S.)Food and Drug Administration (FDA) in 1978, asparaginases have since become an essential component of multi-agent chemotherapy for pediatric and adult acute lymphoblastic leukemia (ALL). This evidence concerns the gene ASPG and acute lymphoblastic leukemia.